<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29535835</article-id><article-id pub-id-type="pmc">5828200</article-id><article-id pub-id-type="publisher-id">24369</article-id><article-id pub-id-type="doi">10.18632/oncotarget.24369</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Curcuminoid submicron particle ameliorates cognitive deficits and decreases amyloid pathology in Alzheimer&#x02019;s disease mouse model</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Tai</surname><given-names>Yi-Heng</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lin</surname><given-names>Yu-Yi</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Kai-Chen</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Chao-Lin</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ru-Yin</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Chia-Chu</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Irene H.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan</aff><aff id="A2"><sup>2</sup> Department of Neurology, Cheng-Hsin General Hospital, Taipei, Taiwan</aff><aff id="A3"><sup>3</sup> Food Industry Research and Development Institute, Hsinchu, Taiwan</aff><aff id="A4"><sup>4</sup> Brain Research Center, National Yang-Ming University, Taipei, Taiwan</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Irene H. Cheng,</italic><email>hjcheng@ym.edu.tw</email></corresp></author-notes><pub-date pub-type="collection"><day>13</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>31</day><month>1</month><year>2018</year></pub-date><volume>9</volume><issue>12</issue><fpage>10681</fpage><lpage>10697</lpage><history><date date-type="received"><day>29</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2018 Tai et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link> (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and is triggered via abnormal accumulation of amyloid-&#x003b2; peptide (A&#x003b2;). Aggregated A&#x003b2; is responsible for disrupting calcium homeostasis, inducing neuroinflammation, and promoting neurodegeneration. In this study, we generated curcuminoid submicron particle (CSP), which reduce the average size to ~60 nm in diameter. CSP had elevated the bioavailability <italic>in vivo</italic> and better neuroprotective effect against oligomeric A&#x003b2; than un-nanosized curcuminoids <italic>in vitro</italic>. Two months of CSP consumption reversed spatial memory deficits and the loss of a calcium binding protein calbindin-D<sub>28k</sub> in the hippocampus of AD mouse model. In addition, CSP consumption lowered amyloid plaques and astrogliosis <italic>in vivo</italic> and enhanced microglial A&#x003b2; phagocytosis <italic>in vitro</italic>, implying that the beneficial effects of CSP also mediated via modulating neuroinflammation and enhancing amyloid clearance. Taken together, our study demonstrated the protective effects of CSP toward ameliorating the memory impairment and pathological deficits in AD mouse model.</p></abstract><kwd-group><kwd>Alzheimer&#x02019;s disease</kwd><kwd>curcuminoid submicron particle</kwd><kwd>APP transgenic mouse</kwd><kwd>amyloid</kwd><kwd>curcumin</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Alzheimer's disease (AD) is the most common form of dementia affecting more than 46 million patients worldwide. Abnormal accumulation of extracellular amyloid-&#x003b2; peptide (A&#x003b2;) into amyloid plaques in the brain is one of the pathological hallmarks of AD. A&#x003b2; is produced through the sequential proteolysis processing of amyloid precursor protein (APP) by &#x003b2;- and &#x003b3;-secretases. Among different length of A&#x003b2;, A&#x003b2;40 is the most abundant species and accounts for 90% of total A&#x003b2; in the brain. However, A&#x003b2;42 is more aggregation-prone and more neurotoxic than other A&#x003b2; species, and thus play the major pathogenic role in AD [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>]. Overexpression of A&#x003b2; deteriorates the cognitive function; on the contrary, reduced levels of A&#x003b2; are often associated with alleviating the cognitive deficits [<xref rid="R3" ref-type="bibr">3</xref>]. Impaired clearance of A&#x003b2; is one of the major the factors that result in the cognitive dysfunction in sporadic AD patients [<xref rid="R4" ref-type="bibr">4</xref>].</p><p>Neuroinflammation triggered by the activation of astrocyte and microglia plays a central role in the pathogenesis of AD [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>]. Astrocytes are a key regulator of neuroinflammation and important for maintaining neuronal functions. Extensive proliferation of astrocytes induced by A&#x003b2; with a reactive phenotype and abnormal regulation leads to cognitive decline in AD [<xref rid="R7" ref-type="bibr">7</xref>]. Microglia, the primary immune cells of the brain, play an important role in maintaining neuronal function and protecting the brain from insults. The activation of microglia has both beneficial and detrimental roles in AD. Activated microglia could be classified into two phenotypes: M1 inflammatory microglia and M2 anti-inflammatory microglia [<xref rid="R8" ref-type="bibr">8</xref>]. M1 phenotype microglia can be triggered by A&#x003b2; to produce pro-inflammatory cytokines, which drive downstream cytokine storm to induce cytotoxicity [<xref rid="R9" ref-type="bibr">9</xref>]. In contrast, M2 phenotype microglia play protective roles against A&#x003b2; -induced damages [<xref rid="R10" ref-type="bibr">10</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>].</p><p>Curcuminoid is a group of natural polyphenol consisted of diarylheptanoid compounds derived from the rhizomes of <italic>Curcuma Longa</italic>, such as curcumin and demethoxycurcumin. Epidemiological studies suggested that curcuminoid consumption is highly associated with the lower prevalence of AD in India [<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>]. In addition, curcumin could inhibit neuroinflammation and reduce amyloid deposition in AD mouse model [<xref rid="R15" ref-type="bibr">15</xref>&#x02013;<xref rid="R17" ref-type="bibr">17</xref>]. However, curcumin intake failed to reduce the amyloid levels in AD patients in the clinical trial [<xref rid="R18" ref-type="bibr">18</xref>]. The major limitation using curcuminoid as a treatment/protective agent is its low bioavailability, which is caused by its poor water solubility and low absorption rate in the gastrointestinal tract [<xref rid="R19" ref-type="bibr">19</xref>, <xref rid="R20" ref-type="bibr">20</xref>]. Several approaches have been applied to overcome this problem, including structural modifications, pharmaceutical adjuvants, liposomes, and nanoparticles [<xref rid="R19" ref-type="bibr">19</xref>, <xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref>]. However, none of them significantly improve the spatial memory deficits in AD mouse model. Nanoparticle technology has emerged as a promising access to enhance bioavailability of lipophilic molecules such as curcumin [<xref rid="R22" ref-type="bibr">22</xref>&#x02013;<xref rid="R24" ref-type="bibr">24</xref>]. The advantage of this nanoparticle technology is to reduce the average size of curcuminoid without structure modification that may alter curcuminoid nature properties.</p><p>In this study, we produced curcuminoid submicron particle (CSP) to average size around 60 nm in diameter and investigate the neuroprotective effects of CSP <italic>in vitro</italic> and <italic>in vivo</italic>. We found that CSP had higher bioavailability, improved spatial learning and memory, and reduced amyloid pathology in APP transgenic mouse. Furthermore, CSP could inhibit neuroinflammation and promote phagocytosis to clear A&#x003b2;. Our study suggested a potential use of CSP for future AD intervention.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>CSP had better protective effect against oligomeric A&#x003b2; <italic>in vitro</italic></title><p>To compare the neuroprotective effect, oligomeric A&#x003b2; (oA&#x003b2;) treated SH-SY5Y human neuroblastoma cells were co-incubated with 5 &#x003bc;M curcuminoid submicron particle (CSP) or un-nanosized curcuminoids (C) for 48 hours, and their viability was determined by MTT assay. The survival rate in oA&#x003b2; treated cells was significantly decreased compared with non-treated cells. Co-incubation with 0.044 and 0.22 &#x003bc;M CSP or un-nanosized curcuminoids significantly reversed oA&#x003b2;-induced neuronal death. In particular, 0.22 &#x003bc;M CSP treated cells had significantly higher survival rate than un-nanosized curcuminoids under A&#x003b2; stress (Figure <xref ref-type="fig" rid="F1">1</xref>). Because CSP had better neuroprotective effect against A&#x003b2; <italic>in vitro</italic>, we further tested the potential use of it to prevent neurodegeneration <italic>in vivo</italic>.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>CSP had better protective effect against oligomeric A&#x003b2; (oA&#x003b2;) than un-nanosized curcuminoid <italic>in vitro</italic></title><p>SH-SY5Y cells were pre-treated with 0, 0.044 or 0.22 &#x003bc;M curcuminoid submicron particle (CSP) or 0.22 &#x003bc;M un-nanosized curcuminoid (C) for 4 hours and then co-treated with 5 &#x003bc;M oA&#x003b2; for 48 hours. The cell survival rate was determined by MTT assay in 3 independent experiments (N&#x0200a;=&#x0200a;8 per experiment). Results were analyzed by one-way ANOVA. <sup>***</sup>, P &#x0003c; 0.001; <sup>**</sup>, P &#x0003c; 0.01; <sup>*</sup>, P &#x0003c; 0.05. The survival rate of SH-SY5Y cells treated with vesicle control was set as 1.</p></caption><graphic xlink:href="oncotarget-09-10681-g001"/></fig></sec><sec id="s2_2"><title>Genotoxicity and biosafety of CSP</title><p>Before applying to AD animal model, we first examined the biosafety of CSP after oral consumption. The acute genotoxicity of CSP was determined using micronucleus assay. ICR male mice were administrated with 0.03, 0.3, and 3 g/kg of CSP, vesicle (negative control), or cyclophosphamide (positive control). The percentage of micronucleated erythrocytes in plasma was used as an indicator of chemical-induced genotoxicity. The percentage of micronucleated erythrocytes in CSP treated groups had no significant difference in comparison with vesicle control group, suggesting that CSP did not induce significant genomic instability and toxicity (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 1</xref>).</p><p>The biosafety of CSP was determined by administration of 0, 0.1, 0.5, and 1.0 g/kg /day of CSP to male and female Sprague-Dawley (SD) rats for continuous 28 days (short-term) and 90 days (long-term). All groups had no apparent adverse effects and recorded death (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>). Furthermore, there were no significant changes in average body weight (Figure <xref ref-type="fig" rid="F2">2A-2B</xref>), and organ weights (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3-4</xref>) among these groups.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Body weight of SD rats in the oral toxicity study of CSP</title><p>Male (black) and female (red) SD rats received 0 (&#x025cf;), 0.1 (&#x02584;), 0.5 (&#x025b2;), and 1 (&#x025bc;) g/kg/day of CSP <bold>(A)</bold> for 28 days and <bold>(B)</bold> 90 days. N = 6 mice/group in 28-day test. N = 8 mice/group in 90-day test. Results were analyzed by one-way ANOVA.</p></caption><graphic xlink:href="oncotarget-09-10681-g002"/></fig></sec><sec id="s2_3"><title>Bioavailability of CSP</title><p>Low bioavailability is one of the major hinders of curcuminoid to be applied as a therapeutic agent [<xref rid="R18" ref-type="bibr">18</xref>]. To assess the bioavailability of CSP, ICR mice were gavaged with low dose (0.2 g/kg) or high dose (2.5 g/kg) of un-nanosized curcuminoids (C) or curcuminoid submicron particle (CSP), and their plasma were collected at 0, 15, 30, 45, 60, 120, and 300 minutes after gavaging. The level of un-nanosized curcuminoids or CSP in plasma was determined by high-pressure liquid chromatography (HPLC). The pharmacokinetic analysis indicated that the CSP had 35-folded higher absorbability than un-nanosized curcuminoids in high dose group (Table <xref ref-type="table" rid="T1">1</xref>), illustrating that reducing the particle size could effectively improve the pharmacokinetic properties of curcuminoids.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Pharmacokinetic analysis of un-nanosized curcuminoid (C) and curcuminoid submicron particle (CSP)</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Treatment</th><th align="center" valign="top" rowspan="1" colspan="1">Dosage (g/kg)</th><th align="center" valign="top" rowspan="1" colspan="1">C<sub>max</sub> (&#x003bc;g/ml)</th><th align="center" valign="top" rowspan="1" colspan="1">T<sub>max</sub> (min)</th><th align="center" valign="top" rowspan="1" colspan="1">AUC (&#x003bc;g/ml&#x02219;min)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;C</td><td rowspan="2" align="center" valign="middle" colspan="1">0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.47&#x000b1;0.33</td><td align="center" valign="top" rowspan="1" colspan="1">45&#x000b1;11</td><td align="center" valign="top" rowspan="1" colspan="1">36&#x000b1;12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;CSP</td><td align="center" valign="top" rowspan="1" colspan="1">5.96&#x000b1;0.72</td><td align="center" valign="top" rowspan="1" colspan="1">75&#x000b1;42</td><td align="center" valign="top" rowspan="1" colspan="1">1,250&#x000b1;56</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ratio (CSP/C)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">12.62</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">35.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;C</td><td rowspan="2" align="center" valign="middle" colspan="1">2.5</td><td align="center" valign="top" rowspan="1" colspan="1">1.83&#x000b1;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">48&#x000b1;7</td><td align="center" valign="top" rowspan="1" colspan="1">276&#x000b1;21</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;CSP</td><td align="center" valign="top" rowspan="1" colspan="1">12.70&#x000b1;1.01</td><td align="center" valign="top" rowspan="1" colspan="1">55&#x000b1;7</td><td align="center" valign="top" rowspan="1" colspan="1">1,884&#x000b1;57</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ratio (CSP/C)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">6.96</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">6.82</td></tr></tbody></table><table-wrap-foot><p>C<sub>max</sub>: peak concentration. T<sub>max</sub>: time to reach peak concentration. AUC: area under curve (plasma concentration-time). C: curcuminoid. CSP: curcuminoid submicron particle. Quantitative data are listed as the mean &#x000b1; standard deviation.</p></table-wrap-foot></table-wrap></sec><sec id="s2_4"><title>CSP ameliorated spatial learning and memory deficit of APP mice</title><p>The neuroprotective effects of CSP <italic>in vivo</italic> were examined using APP transgenic mouse (line J20), which generates high level of A&#x003b2; [<xref rid="R25" ref-type="bibr">25</xref>] and has age-dependent functional and pathological deficits onset at 4 months of age [<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R27" ref-type="bibr">27</xref>]. APP mice and wild-type (WT) littermate controls were administered with CSP or vesicle control at 0.75 mg/ml in drinking water starting at 3 months of age for two months. The average amount of CSP consumption was 37.5 mg/kg/day. These mice had no significant difference in average body weight (Figure <xref ref-type="fig" rid="F3">3A</xref>) and water intake (Figure <xref ref-type="fig" rid="F3">3B</xref>) after 2 months treatment. AD-like functional and pathological deficits were examined in following four groups: wild-type fed with vesicle (WT), wild-type fed with CSP (WT/CSP), APP fed with vesicle, and APP fed with CSP (APP/CSP).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Body weight and water intake of WT and APP mice during CSP treatment</title><p>APP and wildtype littermate control (WT) mice received 0 or 0.75 mg/mL/day of CSP for 2 months. <bold>(A)</bold> Body weight and <bold>(B)</bold> water intake were recorded weekly during CSP administration. N = 12-17 mice/group. Results were analyzed by one-way ANOVA.</p></caption><graphic xlink:href="oncotarget-09-10681-g003"/></fig><p>To elucidate whether CSP could improve cognitive impairment of APP mice [<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R28" ref-type="bibr">28</xref>], the Morris water maze was adopted to evaluate spatial memory deficits the in these 4 groups of mice. In memory acquisition session, the escape latency to reach the hidden platform was longer in APP mice than WT mice. APP/CSP mice exhibited significantly shorter escape latency than APP mice in the last 4 days (Figure <xref ref-type="fig" rid="F4">4A</xref>). In probe trial for memory retention, APP mice spent significantly less time in the platform region than WT, and APP/CSP mice spent significantly longer time in the platform region than APP mice (Figure <xref ref-type="fig" rid="F4">4B-4C</xref>). There was no difference between WT and WT/CSP groups in all the tests. The swimming speeds among each group had no significant difference (Figure <xref ref-type="fig" rid="F4">4D</xref>), suggesting that the reverse of memory deficits in APP/CSP mice was not due the impairment in motor function. Our results demonstrated that CSP significantly improved both memory acquisition and the memory retention deficits in APP mice.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>CSP ameliorated the spatial learning and memory of APP mice in the Morris water maze</title><p><bold>(A)</bold> In hidden platform test, APP/CSP mice had a lower escape latency than APP mice given the control diet. <bold>(B)</bold> In probe trial, APP/CSP mice spent more time in platform region than APP mice. <bold>(C)</bold> Representative traces of each group in the probe trial. &#x025cb; = platform location. <bold>(D)</bold> Swimming speed had no significant difference among all four groups. N = 12-17/group. Results were analyzed by one-way ANOVA.<sup>*</sup>, p &#x0003c; 0.05; <sup>***</sup>, p &#x0003c; 0.001.</p></caption><graphic xlink:href="oncotarget-09-10681-g004"/></fig></sec><sec id="s2_5"><title>CSP did not alter anxiety and locomotor behaviors of APP mice</title><p>Before and after CSP consumption, we used the elevated plus maze to screen for anxiety-related behavior, and the open field test to monitor anxiety and locomotor activity. Compared with WT mice, APP mice spent more time in the open arm of the elevated plus maze (Figure <xref ref-type="fig" rid="F5">5A-5B</xref>), and traveled a longer distance and explored in the center region more frequently in the open field (Figure <xref ref-type="fig" rid="F5">5C-5F</xref>), consistent with previous findings [<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>]. In the elevated plus maze, 2 months of CSP treatment did not significantly reverse the higher open arm time in APP mice (Figure <xref ref-type="fig" rid="F5">5A-5B</xref>). Nevertheless, in the open field, 2 months of CSP treatment reduced the number of center entries (Figure <xref ref-type="fig" rid="F5">5C-5D</xref>) but did not alter the total distance moved in APP mice (Figure <xref ref-type="fig" rid="F5">5E-5F</xref>). Compared with WT mice, WT/CSP mice had no change in anxiety-related behavioral or locomotor activity. In summary, CSP did not influence locomotor activity and only partially reversed anxiety-related behavioral in APP mice.</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Effect of CSP on anxiety-related behavior and locomotor activities of APP mice</title><p><bold>(A-B)</bold> In elevated plus maze, anxiety behavior of these mice was measured by time in open arms before (A) and after (B) CSP treatment. <bold>(C-F)</bold> In open field, anxiety was measured by the number of center entries (C, D) and locomotor activity was measured by total distance traveled (e, f) before and after CSP consumption. N = 12-17 mice/group. Results were analyzed by two-way ANOVA. <sup>*</sup>, p &#x0003c; 0.05; <sup>**</sup>, p &#x0003c; 0.01; <sup>***</sup>, p &#x0003c; 0.001.</p></caption><graphic xlink:href="oncotarget-09-10681-g005"/></fig></sec><sec id="s2_6"><title>CSP reversed the calbindin-D<sub>28K</sub> level in the hippocampus of APP mice</title><p>Memory deficits in APP mice are correlated with the reduced levels of a calcium-binding protein calbindin-D<sub>28K</sub> and calcium dysregulation in the dentate gyrus [<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R29" ref-type="bibr">29</xref>]. Therefore, the expression of calbindin-D<sub>28K</sub> was used to as a marker to examine calcium homeostasis in our mice. We found that the level of calbindin-D<sub>28K</sub> was significantly reduced in APP mice compared to WT mice, but this reduction can be alleviated by CSP consumption in APP mice (Figure <xref ref-type="fig" rid="F6">6A-6D</xref>), implying that memory decline in APP mice rescued by CSP could be associated with the revered levels of calbindin-D<sub>28K</sub> in the dentate gyrus.</p><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>CSP reversed the calbindin-D<sub>28K</sub> level in the hippocampus of APP mice</title><p><bold>(A)</bold> Representative calbindin-D<sub>28K</sub> images in the hippocampus of WT, APP, APP/CSP mice. <bold>(B)</bold> Normalized intensity of calbindin-D<sub>28K</sub> in the dentate gyrus of the hippocampus in each group. N = 6 mice/group, 8-10 brain slices per mouse. Results were analyzed by one-way ANOVA. <sup>***</sup>, p &#x0003c; 0.001. Scale bar = 200 &#x003bc;m.</p></caption><graphic xlink:href="oncotarget-09-10681-g006"/></fig></sec><sec id="s2_7"><title>CSP decreased the amyloid level and astrogliosis in the hippocampus of APP mice</title><p>A&#x003b2; deposition is one of the most important pathological hallmarks of AD. Among different length of A&#x003b2; peptides, A&#x003b2;42 is more aggregation-prone and more neurotoxic than other A&#x003b2; species [<xref rid="R3" ref-type="bibr">3</xref>]. To investigate whether CSP alters A&#x003b2; level in APP mice, we monitored the appearance of amyloid plaques with thioflavin-S staining and the level of A&#x003b2; with enzyme-linked immunosorbent assay (ELISA). The number of amyloid plaques (Figure <xref ref-type="fig" rid="F7">7A-7B</xref>) and the level of A&#x003b2;42 (Figure <xref ref-type="fig" rid="F7">7C</xref>) were significantly decreased in the hippocampus of APP/CSP mice compared to those of APP mice. However, there were no significant reductions in total A&#x003b2; level (Figure <xref ref-type="fig" rid="F7">7D</xref>) and A&#x003b2;42 to total A&#x003b2; ratio (Figure <xref ref-type="fig" rid="F7">7E</xref>) between APP/CSP mice and APP mice. These results indicated that CSP could effectively inhibit the amyloid and neurotoxic A&#x003b2; 42 levels in AD.</p><fig id="F7" orientation="portrait" position="float"><label>Figure 7</label><caption><title>CSP decreased the amyloid deposition in the hippocampus of APP mice</title><p><bold>(A)</bold> Representative images of &#x003b2;-sheet amyloid plaques in the hippocampus of APP and APP/CSP mice stained by Thioflavin-S. Scale bar = 200 &#x003bc;m. <bold>(B)</bold> Quantitative analysis of the number of the plaques in the hippocampus. N = 6 mice/group, 6-10 slices per mouse. <bold>(C-D)</bold> The levels of A&#x003b2;42 (C) and total A&#x003b2; (D) in the hippocampal lysate were determined by ELISA. <bold>(E)</bold> A&#x003b2;42/total A&#x003b2; were unchanged in APP mice treated with CSP. N = 13-17 mice/group. Results were analyzed by <italic>t</italic> test. <sup>**</sup>, p &#x0003c; 0.01; <sup>***</sup>, p &#x0003c; 0.001 versus APP mice.</p></caption><graphic xlink:href="oncotarget-09-10681-g007"/></fig><p>In addition to amyloid pathology, the inflammatory response in these mice was measured by the activation of astrocyte or microglia. The immunoreactive signals of glial fibrillary acidic protein (GFAP) and ionized calcium-binding adapter molecule 1 (Iba1) were used as astrocyte and microglial markers [<xref rid="R30" ref-type="bibr">30</xref>]. We found that APP mice had higher GFAP and Iba1 intensity than WT mice. Consumption of CSP reduced the intensity of GFAP positive astrocyte in the hippocampus of APP/CSP mice (Figure <xref ref-type="fig" rid="F8">8A-8B</xref>). CSP did not alter the intensity of Iba1-positive microglia in the hippocampus of APP mice (Figure <xref ref-type="fig" rid="F8">8C-8D</xref>). Taken together, CSP could mitigate amyloid pathology and inflammatory reaction in APP mice.</p><fig id="F8" orientation="portrait" position="float"><label>Figure 8</label><caption><title>CSP inhibited astrocyte activation in the hippocampus of APP mice</title><p><bold>(A)</bold> Representative images of GFAP<sup>+</sup> astrocyte activation in the hippocampus of WT, APP and APP/CSP mice. <bold>(B)</bold> Normalized GFAP intensity in the hippocampus in each group. <bold>(C)</bold> Representative images of Iba1<sup>+</sup> microglia in the hippocampus of WT, APP and APP/CSP mice. <bold>(D)</bold> The normalized Iba1 intensity in the hippocampus in each group. N = 6 mice/group, 8-10 brain slices per mouse. Results were analyzed by one-way ANOVA. <sup>*</sup>, p &#x0003c; 0.05; <sup>**</sup>, p &#x0003c; 0.01; <sup>***</sup>, p &#x0003c; 0.001. Scale bar = 200 &#x003bc;m.</p></caption><graphic xlink:href="oncotarget-09-10681-g008"/></fig></sec><sec id="s2_8"><title>CSP promoted the microglial phagocytosis and A&#x003b2; uptake in BV<sub>2</sub> microglia</title><p>Microglia activation could promote phagocytosis to clear A&#x003b2;. Although CSP did not reduce activated microglia, CSP decreased the number of plaques in the hippocampus of APP mice. Therefore, we further identified whether CSP could affect the A&#x003b2; clearance through enhancing the microglial phagocytosis [<xref rid="R3" ref-type="bibr">3</xref>]. To address this question, the BV<sub>2</sub> microglial cell was treated with 0 or 2.2 &#x003bc;M CSP for 1 hour and followed by adding 0.001% fluorescent microspheres beads (Figure <xref ref-type="fig" rid="F9">9A-9B</xref>). We found that CSP treated cells had significantly higher percentage of phagocytosed cells (Figure <xref ref-type="fig" rid="F9">9C</xref>). Furthermore, after co-incubating oA&#x003b2; with or without CSP, the A&#x003b2; level in the medium of A&#x003b2;+CSP-treated microglia was significantly lower than A&#x003b2; only microglia (Figure <xref ref-type="fig" rid="F9">9D</xref>). These results demonstrated that CSP enhances the A&#x003b2; -clearance ability of microglia, thereby ameliorating A&#x003b2;-induced neurodegeneration.</p><fig id="F9" orientation="portrait" position="float"><label>Figure 9</label><caption><title>CSP increased phagocytosis of BV<sub>2</sub> microglia</title><p><bold>(A-B)</bold> Representative images of ingested microspheres (red) in the BV<sub>2</sub> cells (green) treated with 0 or 2.2 &#x003bc;M CSP for 1 hr. Scale bar = 25 &#x003bc;m. <bold>(C)</bold> CSP significantly increased the phagocytosis index. N = 11,480 cells in control group; N = 18,199 cells in CSP treated group. <bold>(D)</bold> BV<sub>2</sub> cells were treated with 1 &#x003bc;M oA&#x003b2; and 0 or 2.2 &#x003bc;M CSP for 24 hrs. Levels of residual A&#x003b2; in the media were lower in the CSP treated group. Results were analyzed by <italic>t</italic> test. <sup>*</sup>, p &#x0003c; 0.05; <sup>**</sup>, p &#x0003c; 0.01.</p></caption><graphic xlink:href="oncotarget-09-10681-g009"/></fig><p>We further determined whether CSP could modulate the ratio of M1/M2 phenotype of microglia. The exposure of BV2 to 5 &#x003bc;M oA&#x003b2; could significantly increase the inducible nitric oxide synthase (iNOS), which is one of the direct consequences of an inflammatory process and commonly uses as a marker for M1 microglia [<xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R32" ref-type="bibr">32</xref>]. The iNOS level was decreased in BV<sub>2</sub> microglia co-treated with 2.2 &#x003bc;M CSP and oA&#x003b2; (Figure <xref ref-type="fig" rid="F10">10A-10B</xref>). However, there was no change in M2 anti-inflammatory markers YM1 and IL-4 (Figure <xref ref-type="fig" rid="F10">10C-10D</xref>). These results suggested that CSP may decrease neuroinflammation but did not alter M1/M2 microglia phenotypes.</p><fig id="F10" orientation="portrait" position="float"><label>Figure 10</label><caption><title>CSP reduced the M1 but did not change the M2 type of microglia under oA&#x003b2; stress</title><p>BV<sub>2</sub> microglia was treated with 5 &#x003bc;M oA&#x003b2; and 2.2 &#x003bc;M CSP for 24 hours. <bold>(A)</bold> Representative immunoblot images for pro-inflammatory M1 type microglia marker iNOS in BV<sub>2</sub> cells. <bold>(B)</bold> The level of iNOS in oA&#x003b2;+CSP treated microglia was significantly lower than oA&#x003b2; treated microglia. <bold>(C-D)</bold> Expression of anti-inflammatory M2 type microglia markers YM1 and IL-4 RNA had no significant difference among all groups. Results were analyzed by one-way ANOVA. <sup>**</sup>, p &#x0003c; 0.01; <sup>***</sup>, p &#x0003c; 0.001.</p></caption><graphic xlink:href="oncotarget-09-10681-g010"/></fig></sec><sec id="s2_9"><title>CSP did not have anti-aggregation effect on A&#x003b2;</title><p>The reduced A&#x003b2; level in APP/CSP mice may also due to the inhibition of A&#x003b2; aggregation by CSP. Curcumin has been reported to reduce the amounts of higher molecular A&#x003b2; aggregates [<xref rid="R16" ref-type="bibr">16</xref>]. To monitor the effect of CSP on A&#x003b2; aggregation, 5 &#x003bc;M monomeric A&#x003b2; was incubated with 0, 22, 44, 220, 440 &#x003bc;M CSP for 24 and 48 hours and subjected to immunoblot analysis. We found that A&#x003b2; aggregates into high molecular weight assemblies (&#x0003e;180 kDa) faster in the presence of CSP, indicating that the reduction of A&#x003b2; deposition in the APP/CSP mice is not due to the blockage of A&#x003b2; aggregation (Figure <xref ref-type="fig" rid="F11">11</xref>).</p><fig id="F11" orientation="portrait" position="float"><label>Figure 11</label><caption><title>CSP did not inhibit A&#x003b2; aggregation <italic>in vitro</italic></title><p>Representative images of A&#x003b2; aggregation states in the presence of CSP. 5&#x003bc;M monomeric A&#x003b2; were co-incubated with 0, 22, 44, 220, and 440 &#x003bc;M CSPs for <bold>(A)</bold> 24 hours and <bold>(B)</bold> 48 hours. The size distribution of aggregated A&#x003b2; was immediately examined by western blot.</p></caption><graphic xlink:href="oncotarget-09-10681-g011"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>This study demonstrated that the nano-sized curcuminoid, CSP, had higher bioavailability and better neuroprotective effects than un-nanosized curcuminoid. CSP treatment significantly ameliorated the cognitive function, reduced the amyloid deposition, decreased astrogliosis, reversed calbindin-D<sub>28k</sub> and enhanced microglial phagocytosis. These findings indicate that CSP has potential to be applied as a prevention agent for AD. Curcumin and curcuminoid do not induce apparent adverse effects up to 8,000 mg/day in healthy adults [<xref rid="R33" ref-type="bibr">33</xref>&#x02013;<xref rid="R35" ref-type="bibr">35</xref>]. We demonstrated that both short term and long term CSP consumption is safe under 1000 mg/kg/day. In this study, the amount of CSP consumption for the mouse was 187.5 mg/kg/day, which is approximately equated to 15.2 mg/kg/day for human [<xref rid="R36" ref-type="bibr">36</xref>]. For a 60 kg adult, daily intake of CSP needs to be 912 mg to reach the similar neuroprotective effect, which is within the safe range for curcuminoid [<xref rid="R37" ref-type="bibr">37</xref>&#x02013;<xref rid="R39" ref-type="bibr">39</xref>].</p><p>Multiple approaches have been applied to increase the bioavailability and enhance the neuroprotective effect of curcumin or curcuminoid. The two most common approaches were structural modification and size reduction [<xref rid="R22" ref-type="bibr">22</xref>&#x02013;<xref rid="R24" ref-type="bibr">24</xref>]. After oral gavage, the plasma concentration of CSP was 6-35 times higher than un-nanosized curcuminoid, which is similar or even better than the bioavailability of curcumin modified by other approaches [<xref rid="R22" ref-type="bibr">22</xref>&#x02013;<xref rid="R24" ref-type="bibr">24</xref>]. Whether curcumin could reverse the memory-related deficits in AD mouse models have diverse results. In other curcumin treated AD mouse model, although curcumin could reverse working memory deficits in Y-maze test [<xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R40" ref-type="bibr">40</xref>], it did not significantly improve the memory retention deficits in the probe trial of the Morris water maze test, which is more related to the condition in AD patients [<xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R41" ref-type="bibr">41</xref>]. The PLGA nanoparticles modified curcumin could only attenuate memory deficits when co-delivering with A&#x003b2; generation inhibitor through intraperitoneal injection to AD mouse model [<xref rid="R42" ref-type="bibr">42</xref>]. In our study, APP/CSP mice performed significantly better in both hidden platform and probe trial tests, suggesting that the improvement in both memory acquisition and retention of AD mouse model. Our results indicated that the therapeutic efficacy of orally administered CSP was greatly increased in comparison with previous studies.</p><p>A&#x003b2; -induced neuroinflammation is mostly mediated through CNS-resident cells, including astrocyte and microglia, rather than invading immune cells [<xref rid="R43" ref-type="bibr">43</xref>]. Reactive astrocytes cause disruptions in synaptic connectivity, imbalance of neurotransmitter homeostasis, and neurodegeneration in AD [<xref rid="R44" ref-type="bibr">44</xref>, <xref rid="R45" ref-type="bibr">45</xref>]. Furthermore, the degree of astrogliosis is correlated with cognitive decline in the brain of AD patients [<xref rid="R46" ref-type="bibr">46</xref>]. In our study, CSP could inhibit reactive astrocyte activation in APP mice, suggesting that CSP could reduce astrocyte-mediated neuroinflammation. On the other hand, although CSP consumption did not alter the intensity of Iba1<sup>+</sup> microglia in APP mice, CSP treatment enhanced phagocytic percentage in BV<sub>2</sub> microglia cells. Therefore, the reduction of amyloid plaques in the hippocampus of APP mice might be mediated by CSP through the microglial engulfment. Dysfunction of microglial phagocytosis in AD patients has been linked to the disrupted clearance of A&#x003b2;, and the enhanced memory impairment [<xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R48" ref-type="bibr">48</xref>]. A curcuminoid compound (bisdemethoxycurcumin) has been shown to increase the A&#x003b2; phagocytosis in the brains of AD patients [<xref rid="R49" ref-type="bibr">49</xref>]. Our results provided consistent evidence that CSP enhances microglial phagocytosis.</p><p>Calcium-binding proteins could regulate calcium homeostasis and protect neuron against calcium-mediated neurotoxicity [<xref rid="R50" ref-type="bibr">50</xref>]. The disruption of calcium-binding proteins signaling impairs the synaptic function [<xref rid="R51" ref-type="bibr">51</xref>]. In the hippocampus, calbindin-D<sub>28k</sub> containing neurons play roles in memory formation and long-term potentiation [<xref rid="R52" ref-type="bibr">52</xref>]. The level of calbindin-D<sub>28k</sub> is highly correlated with memory retention deficits of APP mice [<xref rid="R26" ref-type="bibr">26</xref>]. In our study, the reduced expression of calbindin-D<sub>28k</sub> in APP mice was reversed after CSP consumption, which provided the first indication linking the effects of curcuminoid to the levels of calbindin-D<sub>28k</sub> in AD model.</p><p>In summary, this study demonstrated the beneficial effects of CSP on spatial memory deficits and pathological changes in APP mice. CSP can be easily administered to animal model in drinking water as a stable suspension without noticeable adverse effects. Altogether, CSP could be a potential food supplement for long-term treatment of AD.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Animals</title><p>Short-term (28-day) and long-term (90-day) biosafety tests were performed on male and female SD rats. Micronucleus assay was performed on ICR mice. AD mouse model used in this study is APP transgenic mice (line J20) carrying the human APP minigene with the Swedish (K670N/M671L) and Indiana (V717F) familial mutations. Animals were housed in a specific pathogen-free facility with a light/dark cycle of 12 hours light and 12 hours dark. Food and water for mice were provided ad libitum. Drinking water with 0.75 mg/mL CSP was administrated for mice from 3 to 5 months of ages. The open field and elevated plus maze were performed before and after treatment, and the Morris water maze was carried out after 2 months of CSP consumption. Mice were sacrificed with transcardial perfusion with 0.9% NaCl 2 days after behavioral tests. One hemibrain was drop-fixed in 4% paraformaldehyde for 48 h, and the other hemibrain immediately froze at &#x02212;70&#x000b0;C. The study was approved by the Institutional Animal Care and Use Committee of National Yang-Ming University. All experimental procedures involving animals and their care were carried out in accordance with the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health.</p></sec><sec id="s4_2"><title>Preparation of aqueous dispersion with CSP</title><p>To prepare stabilizer for CSP, 2.5 g L-&#x003b1;-phosphatidylcholine (P7443, Sigma, USA) and 3.42 g sucrose esters (Gemfont Corporation, Taiwan) were sequentially incorporated into 400 mL water. The mixed stabilizer materials were stirred at 25&#x000b0;C, and 40 g curcuminoid powder with curcumin, demethoxycurcumin, and bisdemethoxycurcumin (Toong Yeuan, Taiwan) were added to form a 10 % curcuminoid aqueous solution. This non-homogenously mixed solution was subjected to a high-speed homogenization pretreatment from 4,000 to 6,000g for 10 minutes using a PRO250 homogenizer (PRO Scientific, USA). Next, a nano-grade wet grinder (Netzsch-Fein mahltechnik GmbH, Germany) carried on yttria-stabilized tetragonal zirconia for circulation milling with 0.2 mm beads for 180 minutes to obtain the aqueous dispersion. The average diameter of un-nanosized curcuminoid was 5140&#x000b1;178 nm, and the average diameter of CSP was 59&#x000b1;1 nm. Finally, the nanosized CSP composed of curcumin (83.56%), demethoxycurcumin (14.13%) and bisdemethoxycurcumin (2.31%) was obtained. Right before oral administration, CSP was diluted into the drinking water at concentration 0.75 mg/mL. The vesicle control in this study contain the same stabilizer and went through the same preparation process without adding curcuminoid.</p></sec><sec id="s4_3"><title>Bioavailability and biosafety analysis</title><p>For the pharmacokinetics analysis, ICR mice were administered by oral gavage with 0.2 g/kg or 2.5 g/kg of un-nanosized curcuminoid or CSP. At 15, 30, 45, 60, 120, and 300 minutes after gavage, plasma was collected and processed with sulfatase for 2 hours. The level of curcuminoid in plasma was determined by high-pressure liquid chromatography (HPLC).</p><p>For biosafety test, including genotoxic analysis, short-term and long-term tests were adopted to investigate the potentially harmful effects of CSP. Micronucleation assay was applied to identify the genotoxicity of CSP. ICR mice were administered orally with 0, 0.03, 0.3, 3.0 g/kg of CSP or 0.1 g/kg cyclophosphamide (positive control) for 48 hours. 200 &#x003bc;L plasma was incubated with 50 &#x003bc;L 100 U/mL sulfatase for 2 hours, and 120 &#x003bc;L processed sample was then fixed by frozen methanol (&#x02212;80&#x000b0;C). 12 mL buffer (1.8g NaCl and 0.089g NaHCO<sub>3</sub> in 200 mL sterile water, 4&#x000b0;C) was added to the fixed sample and centrifuged at 1,000 &#x000d7;g for 5 minutes to remove supernatant. Cells were resuspended with 80 &#x003bc;L buffer (10 &#x003bc;L/mL CD71-FITC and 1 mg/mL RNAase) for 30 minutes at 4&#x000b0;C, and then 1 mL protease inhibitor (2.5 &#x003bc;g/mL) was added. The percentage micronucleated reticulocyte in their blood will be analyzed by Flow cytometric-Becton Dickinson FacsCalibur and Cell Quest.</p><p>In short-term and long-term safety tests, SD rats were administered with 0.1, 0.5 and 1.0 g/kg/day CSP, or sterile water, daily for 28 days and 90 days. The clinical condition, body weights, organ weights studies were performed after 28 days and 90 days.</p></sec><sec id="s4_4"><title>Morris water maze</title><p>The water maze consisted of a water pool (122 cm in diameter) containing opaque water and a platform (10 cm in diameter) submerged 1 cm below the water surface. The hidden platform test consisted of 10 sessions over 5 days, and each session comprised three 60-second trials with 15-minute inter-trial intervals. The platform location remained constant during the hidden platform sessions, and the entry points were changed semi-randomly between days. One day after the final day of hidden platform training section, a probe trial was conducted by removing the platform and allowing mice to explore in the pool for 1 minute. The time spent in platform region and swim speed were recorded and analyzed with an EthoVision video tracking system (Noldus, Wageningen, Netherlands).</p></sec><sec id="s4_5"><title>Elevated plus maze</title><p>Elevated plus maze consists of two open arms, two closed arms, and a center area. Mice were habituated in the testing room for 1 hour and then were placed individually at the center of the apparatus to explore for 10 minutes. The time spent and distances moved in each of the arms were recorded and analyzed with an EthoVision video tracking system.</p></sec><sec id="s4_6"><title>Open field</title><p>Mice were habituated in the testing room for 1 hour and were placed in an open arena (24.32 &#x000d7; 24.32 cm<sup>2</sup>) for 15 minutes. Two infrared photobeam sensor frames, each consisting of a 32 &#x000d7; 32 photobeam array, were used to detect movements in the horizontal and vertical plane (Version 2.0, TRU Scan Photobeam LINC, Coulbourn Instruments, PA, USA). The distance mice traveled and center entries were used as parameters to analyze the general activity and anxiety of mice.</p></sec><sec id="s4_7"><title>Enzyme-linked immunosorbent assay (ELISA)</title><p>Frozen hippocampi were homogenized in 5M guanidine/5mM Tris buffer (pH 8.0). The samples were diluted with 0.25 % casein blocking buffer containing 0.5 M guanidine and protease inhibitor mix (04693116001, Roche, Switzerland). Total A&#x003b2; and A&#x003b2;42 levels in the soluble fraction were analyzed with ELISA kits (27729 and 27711, INL, Germany) according to the manufacturer's instructions.</p></sec><sec id="s4_8"><title>Immunohistochemistry and thioflavin-S staining</title><p>Paraformaldehyde-fixed brains were sectioned coronally (at 20&#x003bc;m thickness) using a sliding microtome (CM1900; Leica, Germany). For immunohistochemistry (IHC), slices were blocked with phosphate-buffered saline (PBS) containing 10% fetal bovine serum (FBS) and 0.5% Triton X-100 for 1.5 hours, and incubated with anti-GFAP (Z0334; Dako Cytomation, Denmark), anti-Iba1 (019-19741; Wako, Japan), anti-YM1 (#01404, Stemcell Technologies, Canada) and anti-Calbindin-D<sub>28K</sub> (CB38; Swant, Switzerland) antibodies at 4&#x000b0;C overnight. Slices were then incubated with Alexa Fluor 488-conjugated AffiniPure Goat anti-rabbit IgG secondary antibody (111&#x02013;545&#x02013;003; Jackson ImmunoResearch, USA) for 1.5 hours. For Thioflavin-S staining, slices were stained with 0.015% Thioflavin-S (T1892; Sigma, USA) for 15 minutes at room temperature. After mounting, slides were imaged using a Zeiss fluorescence microscope (Axio Observer A1; Zeiss, Germany).</p></sec><sec id="s4_9"><title>Cell culture</title><p>SH-SY5Y human neuroblastoma cell line was maintained in Minimum Essential Medium (MEM, 41500&#x02013;034; Gibco, USA) plus F-12 nutrient mixture (21700&#x02013;075; Gibco, USA) supplemented with 10% fetal bovine serum (FBS, SH3007; HyClone, USA), 0.11 g/L sodium pyruvate, and 1.69 g/L sodium bicarbonate. BV<sub>2</sub> microglia cell line was maintained in Dulbecco's modified Eagle's medium (DMEM, 12100&#x02013;046; Gibco, USA) supplemented with 10% FBS, 1% L-glutamine (GLL01; Caisson laboratory, USA), and 1.85 g/L sodium bicarbonate. Cell lines were grown at 37&#x000b0;C in a humidified 5% CO<sub>2</sub> chamber.</p></sec><sec id="s4_10"><title><italic>In vitro</italic> A&#x003b2; aggregation</title><p>HFIP treated A&#x003b2; (Ultra-pure A&#x003b2;42, HFIP, A1163-2; Kelowna) was dissolved with DMSO, and the A&#x003b2;-DMSO solution was then added into 10mM Tris/PBS buffer to form 100 uM A&#x003b2; solution. The pallet was further removed from A&#x003b2; solution by centrifugation (17000 &#x000d7;g, 15 min, 4&#x000b0;C). The supernatant of 100 &#x003bc;M A&#x003b2; solution was then kept at 4&#x000b0;C for 24 h to form oligomer A&#x003b2;. The oligomeric A&#x003b2; was characterized by using immunoblotting (Figure <xref ref-type="fig" rid="F11">11A</xref>, CSP=0 &#x003bc;M).</p><p>To determine whether CSP could alter A&#x003b2; aggregation, 5 &#x003bc;M HFIP-A&#x003b2; was incubated with 0, 22, 44, 220, and 440 &#x003bc;M CSP for 24 and 48 hours, and their aggregation status was determined by immunoblotting.</p></sec><sec id="s4_11"><title>Immunoblotting</title><p>Cell lysates (10 &#x003bc;g of total protein) or aggregated A&#x003b2; peptide were separated via 10% Tris-glycine polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride (PVDF, IPVH00010; Millipore, Germany) membranes. Membranes were blocked in casein blocking buffer (B6429; Sigma Aldrich, USA) for 1 hours and probed with primary antibody for anti-iNOS (610328; BD Bioscience, USA), anti-GAPDH (G8795; Sigma Aldrich, USA) or anti-A&#x003b2; (6E10, SIG-39320; Covance, USA) antibodies. Membranes were washed with TBST buffer (150 mM NaCl, 10 Mm Tris-HCl, and 0.05% Tween-20, pH 8.0) and probed with horseradish peroxidase (HRP) conjugated goat anti-mouse IgG and goat anti-rabbit IgG (12&#x02013;349, 12-348; Merck Millipore, Germany). Protein signals were visualized using a chemiluminescent HRP substrate ECL detection system (WBKLS0500; Merck Millipore, Germany) and quantified by a luminescence imaging system (LAS-4000; Fujifilm, Japan).</p></sec><sec id="s4_12"><title>MTT assay</title><p>SHSY-5Y cells reaching 75% confluence were incubated with different concentrations of CSP or un-nanosized curcuminoid for 4 hours at 37&#x000b0;C, and then treated with 5 &#x003bc;M oligomeric A&#x003b2; was added at a final concentration of 5 &#x003bc;M. After 48 hours incubation, medium were removed and 10 &#x003bc;L of 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT, 10 mg/mL) solution were added for 4 hours incubation. Cells were then lysed with 100 &#x003bc;l of lysis buffer (10% SDS and 20 mM HCl) at 37&#x000b0;C overnight. Cell survival was determined according to the optical density at 570 nm with the ELISA reader (TECAN Sunrise&#x02122; Absorbance Reader, Switzerland).</p></sec><sec id="s4_13"><title>Phagocytosis assay</title><p>BV<sub>2</sub> microglial cells were seeded in 24-well plates at a density of approximately 8&#x000d7;10<sup>4</sup> cells in each well. BV<sub>2</sub> cells were incubated in the presence or absence of 2.2 &#x003bc;M CSP for 1 hour and then incubated with 0.001% fluorescent microspheres beads (F8821; Molecular Probes, USA) coated with fetal calf serum for 3 hours incubation at 37&#x000b0;C. Cells were washed with PBS for 3 times and then stained with Iba1 antibody. The cells and beads were visualized using fluorescence microscopy. The average number of ingested beads per cells was determined as phagocytosis index.</p><p>For A&#x003b2; clearance, BV2 microglia cells were seeded at a density of 2&#x000d7;10<sup>5</sup> cells/well on poly-D-lysine coated coverslips. Attached microglia were treated with 1 &#x003bc;M oA&#x003b2; with 0 or 2.2 &#x003bc;M CSP for 24 hours. The levels of A&#x003b2; remaining in the media were determined by A&#x003b2;42 ELISA.</p></sec><sec id="s4_14"><title>Quantitative real-time PCR (Q-PCR)</title><p>The RNA from oA&#x003b2; and CSP treated microglia were purified using TRI reagent (T9424, Sigma, MO, USA), and then immediately reverse transcribed into cDNA by MMLV high-performance reverse transcriptase (RT80125K, Epicentre, WI, USA). The mRNA expression levels were analyzed by using primers mixed with SYBR Green PCR Master Mix (10476600, Roche, Penzberg, Germany). A StepOnePlus Real-Time PCR System (Applied Biosystem, ABI, MA, USA) was used to monitor the changes of fluorescence intensity from PCR products. GAPDH was used as internal control. Primer sequence are: IL-4 F: 5&#x02019;GAC GCC ATG CAC GGA GAT3&#x02019;, R: 5&#x02019;TCT CTG TGG TGT TCT TCG TTG CT3&#x02019;; YM1 F: 5&#x02019;TTC TGG TGA AGG AAA TGC GTA AA3&#x02019;, R: 5&#x02019;GCA GCC TTG GAA TGT CTT TCT C3&#x02019;; GAPDH F: 5&#x02019;GCA TCC ACT GGT GCT GCC3&#x02019;; R: 5&#x02019;TCA TCA TAC TTG GCA GGT TTC3&#x02019;. The data were analyzed using StepOne software version 2.0.</p></sec><sec id="s4_15"><title>Statistical analysis</title><p>Statistical analyses were performed with GraphPad Prism (Version 5.0; GraphPad, USA). Differences among multiple means were assessed by one-way, two-way ANOVA, followed by Bonferroni's post-hoc test or Tukey's multiple comparison test. Differences between two means were assessed by paired or unpaired <italic>t</italic> test. The threshold for significance was defined as p&#x0003c; 0.05. All data are presented as mean &#x000b1;SEM.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY MATERIALS TABLES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-09-10681-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e1137" position="anchor"/></supplementary-material></sec></body><back><ack><title>ACKNOWLEDGMENTS AND FUNDING</title><p>Behavioral studies were carried out at the Animal Behavioral Core at Brain Research Center, National Yang-Ming University. The technical services of confocal images were provided by Imaging Core Facility of Nanotechnology of the UST-NYMU.</p><p>This work was supported by Taiwan Ministry of Science and Technology grant (MOST-105-2320-B-010-031), National Health Research Institutes (NHRI-EX106-10614NI), Cheng Hsin General Hospital (105F003C27), Yen Tjing Ling Medical Foundation (CI-106-2), Ministry of Economic Affairs, ROC (103-EC-17-A-03-04-0332), and Taiwan Ministry of Education Aim for Top University Grant.</p></ack><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>YHT and YYL performed the AD-related experiment and wrote the manuscript. CLC, RYC, and CCW prepared CSP and performed bioavailability and biosafety tests. IHC and KCW designed the experiment and wrote the manuscript.</p></fn><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>The authors declare no conflicts of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Takio</surname><given-names>K</given-names></name><name><surname>Ogawara</surname><given-names>M</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Mass spectrometry of purified amyloid beta protein in Alzheimer's disease</article-title><source>J Biol Chem</source><year>1992</year><volume>267</volume><fpage>17082</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1512246</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitan</surname><given-names>G</given-names></name><name><surname>Kirkitadze</surname><given-names>MD</given-names></name><name><surname>Lomakin</surname><given-names>A</given-names></name><name><surname>Vollers</surname><given-names>SS</given-names></name><name><surname>Benedek</surname><given-names>GB</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name></person-group><article-title>Amyloid beta -protein (abeta) assembly: abeta 40 and abeta 42 oligomerize through distinct pathways</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>330</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12506200</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Querfurth</surname><given-names>HW</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name></person-group><article-title>Alzheimer's disease</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>329</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">20107219</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mawuenyega</surname><given-names>KG</given-names></name><name><surname>Sigurdson</surname><given-names>W</given-names></name><name><surname>Ovod</surname><given-names>V</given-names></name><name><surname>Munsell</surname><given-names>L</given-names></name><name><surname>Kasten</surname><given-names>T</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Yarasheski</surname><given-names>KE</given-names></name><name><surname>Bateman</surname><given-names>RJ</given-names></name></person-group><article-title>Decreased clearance of CNS amyloid-&#x003b2; in Alzheimer's disease</article-title><source>Science</source><year>2010</year><volume>330</volume><fpage>1774</fpage><pub-id pub-id-type="pmid">21148344</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becher</surname><given-names>B</given-names></name><name><surname>Spath</surname><given-names>S</given-names></name><name><surname>Goverman</surname><given-names>J</given-names></name></person-group><article-title>Cytokine networks in neuroinflammation</article-title><source>Nat Rev Immunol</source><year>2017</year><volume>17</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">27916979</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heneka</surname><given-names>MT</given-names></name><name><surname>Carson</surname><given-names>MJ</given-names></name><name><surname>Khoury</surname><given-names>JE</given-names></name><name><surname>Landreth</surname><given-names>GE</given-names></name><name><surname>Brosseron</surname><given-names>F</given-names></name><name><surname>Feinstein</surname><given-names>DL</given-names></name><name><surname>Jacobs</surname><given-names>AH</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Vitorica</surname><given-names>J</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Herrup</surname><given-names>K</given-names></name><name><surname>Frautschy</surname><given-names>SA</given-names></name><name><surname>Finsen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Neuroinflammation in Alzheimer's disease</article-title><source>Lancet Neurol</source><year>2015</year><volume>14</volume><fpage>388</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">25792098</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Arellano</surname><given-names>JJ</given-names></name><name><surname>Parpura</surname><given-names>V</given-names></name><name><surname>Zorec</surname><given-names>R</given-names></name><name><surname>Verkhratsky</surname><given-names>A</given-names></name></person-group><article-title>Astrocytes in physiological aging and Alzheimer's disease</article-title><source>Neuroscience</source><year>2016</year><volume>323</volume><fpage>170</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">25595973</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Le</surname><given-names>W</given-names></name></person-group><article-title>Differential roles of M1 and M2 microglia in neurodegenerative diseases</article-title><source>Mol Neurobiol</source><year>2016</year><volume>53</volume><fpage>1181</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">25598354</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prokop</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>KR</given-names></name><name><surname>Heppner</surname><given-names>FL</given-names></name></person-group><article-title>Microglia actions in Alzheimer's disease</article-title><source>Acta Neuropathol</source><year>2013</year><volume>126</volume><fpage>461</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">24224195</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heneka</surname><given-names>MT</given-names></name><name><surname>Kummer</surname><given-names>MP</given-names></name><name><surname>Stutz</surname><given-names>A</given-names></name><name><surname>Delekate</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Vieira-Saecker</surname><given-names>A</given-names></name><name><surname>Griep</surname><given-names>A</given-names></name><name><surname>Axt</surname><given-names>D</given-names></name><name><surname>Remus</surname><given-names>A</given-names></name><name><surname>Tzeng</surname><given-names>TC</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Halle</surname><given-names>A</given-names></name><name><surname>Korte</surname><given-names>M</given-names></name><etal/></person-group><article-title>NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice</article-title><source>Nature</source><year>2013</year><volume>493</volume><fpage>674</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23254930</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherry</surname><given-names>JD</given-names></name><name><surname>Olschowka</surname><given-names>JA</given-names></name><name><surname>O'Banion</surname><given-names>MK</given-names></name></person-group><article-title>Neuroinflammation and M2 microglia: the good, the bad, and the inflamed</article-title><source>J Neuroinflammation</source><year>2014</year><volume>11</volume><fpage>98</fpage><pub-id pub-id-type="pmid">24889886</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>WT</given-names></name><name><surname>Lin</surname><given-names>YY</given-names></name><name><surname>Lu</surname><given-names>PH</given-names></name><name><surname>Hsieh</surname><given-names>SL</given-names></name><name><surname>Cheng</surname><given-names>IH</given-names></name></person-group><article-title>Amelioration of amyloid-&#x003b2;-induced deficits by DcR3 in an Alzheimer's disease model</article-title><source>Mol Neurodegener</source><year>2017</year><volume>12</volume><fpage>30</fpage><pub-id pub-id-type="pmid">28438208</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>V</given-names></name><name><surname>Pandav</surname><given-names>R</given-names></name><name><surname>Dodge</surname><given-names>HH</given-names></name><name><surname>Johnston</surname><given-names>JM</given-names></name><name><surname>Belle</surname><given-names>SH</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Ganguli</surname><given-names>M</given-names></name></person-group><article-title>Incidence of Alzheimer's disease in a rural community in india: the indo-us study</article-title><source>Neurology</source><year>2001</year><volume>57</volume><fpage>985</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11571321</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vas</surname><given-names>CJ</given-names></name><name><surname>Pinto</surname><given-names>C</given-names></name><name><surname>Panikker</surname><given-names>D</given-names></name><name><surname>Noronha</surname><given-names>S</given-names></name><name><surname>Deshpande</surname><given-names>N</given-names></name><name><surname>Kulkarni</surname><given-names>L</given-names></name><name><surname>Sachdeva</surname><given-names>S</given-names></name></person-group><article-title>Prevalence of dementia in an urban indian population</article-title><source>Int Psychogeriatr</source><year>2001</year><volume>13</volume><fpage>439</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">12003250</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>GP</given-names></name><name><surname>Chu</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>FS</given-names></name><name><surname>Beech</surname><given-names>W</given-names></name><name><surname>Frautschy</surname><given-names>SA</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name></person-group><article-title>The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse</article-title><source>J Neurosci</source><year>2001</year><volume>21</volume><fpage>8370</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11606625</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Lim</surname><given-names>GP</given-names></name><name><surname>Begum</surname><given-names>AN</given-names></name><name><surname>Ubeda</surname><given-names>OJ</given-names></name><name><surname>Simmons</surname><given-names>MR</given-names></name><name><surname>Ambegaokar</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>PP</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><name><surname>Frautschy</surname><given-names>SA</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name></person-group><article-title>Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>5892</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">15590663</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frautschy</surname><given-names>SA</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name></person-group><article-title>Why pleiotropic interventions are needed for Alzheimer's disease</article-title><source>Mol Neurobiol</source><year>2010</year><volume>41</volume><fpage>392</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">20437209</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ringman</surname><given-names>JM</given-names></name><name><surname>Frautschy</surname><given-names>SA</given-names></name><name><surname>Teng</surname><given-names>E</given-names></name><name><surname>Begum</surname><given-names>AN</given-names></name><name><surname>Bardens</surname><given-names>J</given-names></name><name><surname>Beigi</surname><given-names>M</given-names></name><name><surname>Gylys</surname><given-names>KH</given-names></name><name><surname>Badmaev</surname><given-names>V</given-names></name><name><surname>Heath</surname><given-names>DD</given-names></name><name><surname>Apostolova</surname><given-names>LG</given-names></name><name><surname>Porter</surname><given-names>V</given-names></name><name><surname>Vanek</surname><given-names>Z</given-names></name><name><surname>Marshall</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study</article-title><source>Alzheimers Res Ther</source><year>2012</year><volume>4</volume><fpage>43</fpage><pub-id pub-id-type="pmid">23107780</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>P</given-names></name><name><surname>Kunnumakkara</surname><given-names>AB</given-names></name><name><surname>Newman</surname><given-names>RA</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Bioavailability of curcumin: problems and promises</article-title><source>Mol Pharm</source><year>2007</year><volume>4</volume><fpage>807</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">17999464</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begum</surname><given-names>AN</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Lim</surname><given-names>GP</given-names></name><name><surname>Morihara</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>P</given-names></name><name><surname>Heath</surname><given-names>DD</given-names></name><name><surname>Rock</surname><given-names>CL</given-names></name><name><surname>Pruitt</surname><given-names>MA</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Hudspeth</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Faull</surname><given-names>KF</given-names></name><name><surname>Teter</surname><given-names>B</given-names></name><etal/></person-group><article-title>Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease</article-title><source>J Pharmacol Exp Ther</source><year>2008</year><volume>326</volume><fpage>196</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">18417733</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolai</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Corbo</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Averick</surname><given-names>S</given-names></name><name><surname>Obeysekera</surname><given-names>D</given-names></name><name><surname>Farid</surname><given-names>M</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>P</given-names></name><name><surname>Raja</surname><given-names>K</given-names></name></person-group><article-title>&#x0201c;Clicked&#x0201d; sugar-curcumin conjugate: modulator of amyloid-beta and tau peptide aggregation at ultralow concentrations</article-title><source>ACS Chem Neurosci</source><year>2011</year><volume>2</volume><fpage>694</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22860163</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mourtas</surname><given-names>S</given-names></name><name><surname>Canovi</surname><given-names>M</given-names></name><name><surname>Zona</surname><given-names>C</given-names></name><name><surname>Aurilia</surname><given-names>D</given-names></name><name><surname>Niarakis</surname><given-names>A</given-names></name><name><surname>La Ferla</surname><given-names>B</given-names></name><name><surname>Salmona</surname><given-names>M</given-names></name><name><surname>Nicotra</surname><given-names>F</given-names></name><name><surname>Gobbi</surname><given-names>M</given-names></name><name><surname>Antimisiaris</surname><given-names>SG</given-names></name></person-group><article-title>Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>1635</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">21131044</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>A</given-names></name><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Lou</surname><given-names>H</given-names></name><name><surname>Zhai</surname><given-names>G</given-names></name></person-group><article-title>Preparation and characterization of intravenously injectable curcumin nanosuspension</article-title><source>Drug Deliv</source><year>2011</year><volume>18</volume><fpage>131</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">20939679</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Tyagi</surname><given-names>AK</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice</article-title><source>Cancer Res Treat</source><year>2014</year><volume>46</volume><fpage>2</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">24520218</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mucke</surname><given-names>L</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>GQ</given-names></name><name><surname>Mallory</surname><given-names>M</given-names></name><name><surname>Rockenstein</surname><given-names>EM</given-names></name><name><surname>Tatsuno</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Kholodenko</surname><given-names>D</given-names></name><name><surname>Johnson-Wood</surname><given-names>K</given-names></name><name><surname>McConlogue</surname><given-names>L</given-names></name></person-group><article-title>High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation</article-title><source>J Neurosci</source><year>2000</year><volume>20</volume><fpage>4050</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10818140</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Kekonius</surname><given-names>L</given-names></name><name><surname>Chin</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>GQ</given-names></name><name><surname>Raber</surname><given-names>J</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><article-title>Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>9572</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12881482</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>IH</given-names></name><name><surname>Scearce-Levie</surname><given-names>K</given-names></name><name><surname>Legleiter</surname><given-names>J</given-names></name><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Gerstein</surname><given-names>H</given-names></name><name><surname>Bien-Ly</surname><given-names>N</given-names></name><name><surname>Puoliv&#x000e4;li</surname><given-names>J</given-names></name><name><surname>Lesn&#x000e9;</surname><given-names>S</given-names></name><name><surname>Ashe</surname><given-names>KH</given-names></name><name><surname>Muchowski</surname><given-names>PJ</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><article-title>Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>23818</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">17548355</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Chen</surname><given-names>MC</given-names></name><name><surname>Cheng</surname><given-names>IH</given-names></name></person-group><article-title>Antroquinonol lowers brain amyloid-&#x003b2; levels and improves spatial learning and memory in a transgenic mouse model of Alzheimer's disease</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>15067</fpage><pub-id pub-id-type="pmid">26469245</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>J</given-names></name><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Puolivali</surname><given-names>J</given-names></name><name><surname>Massaro</surname><given-names>C</given-names></name><name><surname>Bien-Ly</surname><given-names>N</given-names></name><name><surname>Gerstein</surname><given-names>H</given-names></name><name><surname>Scearce-Levie</surname><given-names>K</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><article-title>Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>9694</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">16237174</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Shuboy</surname><given-names>A</given-names></name><name><surname>Lou</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Curcumin as a potential treatment for Alzheimer's disease: a study of the effects of curcumin on hippocampal expression of glial fibrillary acidic protein</article-title><source>Am J Chin Med</source><year>2013</year><volume>41</volume><fpage>59</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">23336507</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraft</surname><given-names>AD</given-names></name><name><surname>Harry</surname><given-names>GJ</given-names></name></person-group><article-title>Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity</article-title><source>Int J Environ Res Public Health</source><year>2011</year><volume>8</volume><fpage>2980</fpage><lpage>3018</lpage><pub-id pub-id-type="pmid">21845170</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname><given-names>K</given-names></name><name><surname>Maidt</surname><given-names>ML</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Sang</surname><given-names>H</given-names></name><name><surname>Markesbery</surname><given-names>WR</given-names></name><name><surname>Floyd</surname><given-names>RA</given-names></name></person-group><article-title>Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation</article-title><source>J Neurosci</source><year>1998</year><volume>18</volume><fpage>8126</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">9763459</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lao</surname><given-names>CD</given-names></name><name><surname>Ruffin</surname><given-names>MT</given-names><suffix>4th</suffix></name><name><surname>Normolle</surname><given-names>D</given-names></name><name><surname>Heath</surname><given-names>DD</given-names></name><name><surname>Murray</surname><given-names>SI</given-names></name><name><surname>Bailey</surname><given-names>JM</given-names></name><name><surname>Boggs</surname><given-names>ME</given-names></name><name><surname>Crowell</surname><given-names>J</given-names></name><name><surname>Rock</surname><given-names>CL</given-names></name><name><surname>Brenner</surname><given-names>DE</given-names></name></person-group><article-title>Dose escalation of a curcuminoid formulation</article-title><source>BMC Complement Altern Med</source><year>2006</year><volume>6</volume><fpage>10</fpage><pub-id pub-id-type="pmid">16545122</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Lin</surname><given-names>JK</given-names></name><name><surname>Hsu</surname><given-names>MM</given-names></name><name><surname>Ho</surname><given-names>YF</given-names></name><name><surname>Shen</surname><given-names>TS</given-names></name><name><surname>Ko</surname><given-names>JY</given-names></name><name><surname>Lin</surname><given-names>JT</given-names></name><name><surname>Lin</surname><given-names>BR</given-names></name><name><surname>Ming-Shiang</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>HS</given-names></name><name><surname>Jee</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions</article-title><source>Anticancer Res</source><year>2001</year><volume>21</volume><fpage>2895</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">11712783</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Palanivelu</surname><given-names>K</given-names></name></person-group><article-title>The effect of curcumin (turmeric) on Alzheimer's disease: an overview</article-title><source>Ann Indian Acad Neurol</source><year>2008</year><volume>11</volume><fpage>13</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19966973</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reagan-Shaw</surname><given-names>S</given-names></name><name><surname>Nihal</surname><given-names>M</given-names></name><name><surname>Ahmad</surname><given-names>N</given-names></name></person-group><article-title>Dose translation from animal to human studies revisited</article-title><source>FASEB J</source><year>2008</year><volume>22</volume><fpage>659</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">17942826</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frautschy</surname><given-names>SA</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>P</given-names></name><name><surname>Miller</surname><given-names>SA</given-names></name><name><surname>Chu</surname><given-names>T</given-names></name><name><surname>Harris-White</surname><given-names>ME</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name></person-group><article-title>Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology</article-title><source>Neurobiol Aging</source><year>2001</year><volume>22</volume><fpage>993</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">11755008</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Lian</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>Curcumin improves amyloid beta-peptide (1-42) induced spatial memory deficits through BDNF-ERK signaling pathway</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0131525</fpage><pub-id pub-id-type="pmid">26114940</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Mitchell</surname><given-names>ES</given-names></name><name><surname>Xiu</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Tiwari</surname><given-names>JK</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name></person-group><article-title>Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e31211</fpage><pub-id pub-id-type="pmid">22359574</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>QL</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Rosario</surname><given-names>ER</given-names></name><name><surname>Ubeda</surname><given-names>OJ</given-names></name><name><surname>Beech</surname><given-names>W</given-names></name><name><surname>Gant</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>PP</given-names></name><name><surname>Hudspeth</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Frautschy</surname><given-names>SA</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name></person-group><article-title>Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin</article-title><source>J Neurosci</source><year>2009</year><volume>29</volume><fpage>9078</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">19605645</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Teng</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice</article-title><source>Eur J Pharmacol</source><year>2014</year><volume>740</volume><fpage>312</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">25041840</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>XG</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Liu</surname><given-names>RT</given-names></name></person-group><article-title>PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering A&#x003b2; generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>81001</fpage><lpage>13</lpage><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.20944">https://doi.org/10.18632/oncotarget.20944</ext-link><pub-id pub-id-type="pmid">29113362</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heppner</surname><given-names>FL</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Becher</surname><given-names>B</given-names></name></person-group><article-title>Immune attack: the role of inflammation in Alzheimer disease</article-title><source>Nat Rev Neurosci</source><year>2015</year><volume>16</volume><fpage>358</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">25991443</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>MJ</given-names></name><name><surname>Thrash</surname><given-names>JC</given-names></name><name><surname>Walter</surname><given-names>B</given-names></name></person-group><article-title>The cellular response in neuroinflammation: the role of leukocytes, microglia and astrocytes in neuronal death and survival</article-title><source>Clin Neurosci Res</source><year>2006</year><volume>6</volume><fpage>237</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">19169437</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sofroniew</surname><given-names>MV</given-names></name></person-group><article-title>Molecular dissection of reactive astrogliosis and glial scar formation</article-title><source>Trends Neurosci</source><year>2009</year><volume>32</volume><fpage>638</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">19782411</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>JE</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Lace</surname><given-names>G</given-names></name><name><surname>Forster</surname><given-names>G</given-names></name><name><surname>Shaw</surname><given-names>PJ</given-names></name><name><surname>Matthews</surname><given-names>F</given-names></name><name><surname>Savva</surname><given-names>G</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Wharton</surname><given-names>SB</given-names></name><collab>MRC Cognitive Function and Ageing Neuropathology Study Group</collab></person-group><article-title>Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain</article-title><source>Neurobiol Aging</source><year>2010</year><volume>31</volume><fpage>578</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">18586353</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiala</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Ringman</surname><given-names>J</given-names></name><name><surname>Kermani-Arab</surname><given-names>V</given-names></name><name><surname>Tsao</surname><given-names>G</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Lossinsky</surname><given-names>AS</given-names></name><name><surname>Graves</surname><given-names>MC</given-names></name><name><surname>Gustavson</surname><given-names>A</given-names></name><name><surname>Sayre</surname><given-names>J</given-names></name><name><surname>Sofroni</surname><given-names>E</given-names></name><name><surname>Suarez</surname><given-names>T</given-names></name><name><surname>Chiappelli</surname><given-names>F</given-names></name><name><surname>Bernard</surname><given-names>G</given-names></name></person-group><article-title>Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients</article-title><source>J Alzheimers Dis</source><year>2005</year><volume>7</volume><fpage>221</fpage><lpage>32</lpage><comment>discussion 55-62</comment><pub-id pub-id-type="pmid">16006665</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bard</surname><given-names>F</given-names></name><name><surname>Cannon</surname><given-names>C</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Burke</surname><given-names>RL</given-names></name><name><surname>Games</surname><given-names>D</given-names></name><name><surname>Grajeda</surname><given-names>H</given-names></name><name><surname>Guido</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Johnson-Wood</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Kholodenko</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><etal/></person-group><article-title>Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><fpage>916</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10932230</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiala</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>PT</given-names></name><name><surname>Espinosa-Jeffrey</surname><given-names>A</given-names></name><name><surname>Rosenthal</surname><given-names>MJ</given-names></name><name><surname>Bernard</surname><given-names>G</given-names></name><name><surname>Ringman</surname><given-names>JM</given-names></name><name><surname>Sayre</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zaghi</surname><given-names>J</given-names></name><name><surname>Dejbakhsh</surname><given-names>S</given-names></name><name><surname>Chiang</surname><given-names>B</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Mahanian</surname><given-names>M</given-names></name><etal/></person-group><article-title>Innate immunity and transcription of MGAT-III and toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>12849</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">17652175</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagerl</surname><given-names>UV</given-names></name><name><surname>Mody</surname><given-names>I</given-names></name><name><surname>Jeub</surname><given-names>M</given-names></name><name><surname>Lie</surname><given-names>AA</given-names></name><name><surname>Elger</surname><given-names>CE</given-names></name><name><surname>Beck</surname><given-names>H</given-names></name></person-group><article-title>Surviving granule cells of the sclerotic human hippocampus have reduced Ca(2+) influx because of a loss of calbindin-D(28k) in temporal lobe epilepsy</article-title><source>J Neurosci</source><year>2000</year><volume>20</volume><fpage>1831</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10684884</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kook</surname><given-names>SY</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>MJ</given-names></name><name><surname>Park</surname><given-names>R</given-names></name><name><surname>Shin</surname><given-names>HJ</given-names></name><name><surname>Han</surname><given-names>SH</given-names></name><name><surname>Son</surname><given-names>SM</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Baik</surname><given-names>SH</given-names></name><name><surname>Moon</surname><given-names>M</given-names></name><name><surname>Yi</surname><given-names>EC</given-names></name><name><surname>Hwang</surname><given-names>D</given-names></name><name><surname>Mook-Jung</surname><given-names>I</given-names></name></person-group><article-title>Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model</article-title><source>Cell Death Differ</source><year>2014</year><volume>21</volume><fpage>1575</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">24853300</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molinari</surname><given-names>S</given-names></name><name><surname>Battini</surname><given-names>R</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Pozzi</surname><given-names>L</given-names></name><name><surname>Killcross</surname><given-names>AS</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Jouvenceau</surname><given-names>A</given-names></name><name><surname>Billard</surname><given-names>JM</given-names></name><name><surname>Dutar</surname><given-names>P</given-names></name><name><surname>Lamour</surname><given-names>Y</given-names></name><name><surname>Baker</surname><given-names>WA</given-names></name><name><surname>Cox</surname><given-names>H</given-names></name><name><surname>Emson</surname><given-names>PC</given-names></name></person-group><article-title>Deficits in memory and hippocampal long-term potentiation in mice with reduced calbindin D28K expression</article-title><source>Proc Natl Acad Sci U S A</source><year>1996</year><volume>93</volume><fpage>8028</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">8755597</pub-id></element-citation></ref></ref-list></back></article>